Catalyst Pharmaceuticals: Angelini Deal Caps A Potentially Better Story (NASDAQ:CPRX)

CPRX Q1 2026 revenue surged as Firdapse and Agamree drive growth; Angelini’s $31.50 offer limits upside.

Read on WOBR AI →